BNTC · long Benitec Biopharma INC
Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.
NASDAQ
Benitec Biopharma Inc.
BNTC
1 story
$314M Market cap · 2026-10-07
BNTC · long BNTC · long 
NASDAQ
BNTC
1 story
$314M Market cap · 2026-10-07
BNTC · long Benitec Biopharma's BB-301 gene therapy is in a Phase 1b/2a trial for an ultra-rare muscular dystrophy.